/

Empresas

Ca

No verificado

CatalYm

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

13 Comunicados de prensa

Ver todos los comunicados de prensa

24/10/2026

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

Biotecnología

Ferias y Congresos

Industria

CatalYm Presents Phase 2 Data Showing Visugromab Substantially Enhances the Clinical Benefit of PD-1 Inhibition in Neoadjuvant Bladder Cancer at ESMO 2026

Fuente

Editor

1.00

0

06/10/2026

Eventos

Industria

Ciencia

Medicina - Varios

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

CatalYm to Present Updated GDFATHER-NEO Clinical Data and Highlight Ongoing Phase 2b Visugromab Trials at ESMO 2026

Fuente

Editor

1.00

0

09/06/2026

Mercado laboral

Ciencia

Medicina - Varios

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

CatalYm Appoints Peter Garcia as Chief Financial Officer

Fuente

Editor

1.00

0

07/04/2026

Industria

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

CatalYm Doses First Patient in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Unresectable/Metastatic Hepatocellular Carcinoma

Fuente

Editor

1.00

0

02/12/2025

Industria

Ciencia

Medicina - Varios

Biotecnología

Sanidad

Salud

Farmacéutica

Oncología

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as Second-Line Treatment in Metastatic Non-squamous NSCLC

Fuente

Editor

1.00

0

17/10/2025

Oncología

Salud

Biotecnología

Sanidad

Medicina - Varios

Farmacéutica

Eventos

Ferias y Congresos

Industria

CatalYm Presents Phase 2 Data in Neoadjuvant Bladder Cancer Demonstrating Substantial Increase of Anti-Tumor Activity for Visugromab in Combination with PD-1 Inhibitor at ESMO

Fuente

Editor

1.00

0

30/09/2025

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

Industria

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC

Fuente

Editor

1.00

0

30/09/2025

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

Industria

CatalYm Announces First Patient Dosed in Phase 2b Trial Evaluating Visugromab in Combination with Chemoimmunotherapy as First-Line Treatment in Metastatic Non-squamous NSCLC

Fuente

Editor

1.00

0

22/09/2025

Ferias y Congresos

Industria

Oncología

Salud

Medicina - Varios

Ciencia

Farmacéutica

CatalYm to Present Primary Results From Phase 2 Neoadjuvant Bladder Cancer Trial in Late-breaking Oral Presentation at ESMO

Fuente

Editor

1.00

0

09/01/2025

Mercado laboral

Ciencia

Biotecnología

Farmacéutica

Oncología

Salud

Medicina - Varios

CatalYm Appoints Scott Clarke CEO as Company Initiates Global Phase 2b Clinical Development Program for Visugromab

Fuente

Editor

1.00

0

Seguidores

0

Compatibilidad

0